UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
Amendment No. 1
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 28, 2016
AEGERION PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-34921 |
|
20-2960116 |
(State or other jurisdiction |
|
(Commission |
|
(IRS Identification No.) |
One Main Street, Suite 800, Cambridge, Massachusetts |
|
02142 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrants telephone number, including area code: (617) 500-7867
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)
o Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Explanatory Note
This report amends the Current Report on Form 8-K filed by Aegerion Pharmaceuticals, Inc. (the Company) on February 3, 2016 (the Original Filing) to provide information regarding the employment arrangement of Gregory Perry, the Companys Chief Financial Officer and Administrative Officer, that was unavailable at the time of the Original Filing.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As previously reported in the Original Filing, Mr. Perry was appointed as the Companys Chief Financial and Administrative Officer effective January 28, 2016. On February 11, 2016, the Compensation Committee (the Compensation Committee) of the Companys Board of Directors approved an increase in Mr. Perrys salary to $450,000 effective as of February 12, 2016 and that Mr. Perry will be eligible to receive an annual cash bonus of up to 50% of his base salary based on the achievement of certain corporate goals. In addition, the Compensation Committee approved one-time cash incentive bonus payments to Mr. Perry of up to a total of $450,000, subject to the achievement of certain strategic corporate events in 2016 and Mr. Perrys continued employment with the Company. The Compensation Committee also approved a stock option grant to Mr. Perry, exercisable for 200,000 shares of the Companys common stock; 25% of the shares of common stock underlying the stock option award vested on February 12, 2016 and the remaining 75% of the shares of common stock underlying such award will vest in equal annual installments on December 31, 2016, December 31, 2017 and December 31, 2018, subject to Mr. Perrys continued employment with the Company.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: February 17, 2016
|
AEGERION PHARMACEUTICALS, INC. | |
|
| |
|
| |
|
By: |
/s/ Benjamin Harshbarger |
|
|
Benjamin Harshbarger |
|
|
Acting General Counsel |